Establishment of childhood hepatoblastoma xenografts and evaluation of the anti-tumour effects of anlotinib, oxaliplatin and sorafenib

Researchers established a patient-derived xenograft model of childhood hepatoblastoma that maintains original tumor characteristics. Testing revealed anlotinib, oxaliplatin, and sorafenib significantly inhibited tumor growth with minimal toxicity, providing preclinical evidence for potential new treatment options beyond standard platinum-based chemotherapy.